Monoamine oxidase inhibitors: A paradigm of poor science

Abstract

Get full access to this article

View all access options for this article.

References

Ashcroft

(2004) Current epistemological problems in evidence based medicine. Journal of Medical Ethics 30: 131–135.

Bernard

(1865) A N’etude de la medecin eexperimentale (Trans. Greene

, 1927). Bailliere.

Boudry

Paglieri

Pigliucci

(2015) The fake, the flimsy, and the fallacious: Demarcating arguments in real life. Argumentation 29(4): 431–456.

Buckley

Dawson

Isbister

(2014) Serotonin syndrome. BMJ 348: g1626.

Byrne

Doyle

Brannick

, et al. (2024) Evaluating the psychometric structure of the Hamilton Rating Scale for Depression pre- and post-treatment in antidepressant randomised trials: Secondary analysis of 6843 individual participants from 20 trials. Psychiatry Research 339: 116057.

Cartwright

(2007) Are RCTs the gold standard? BioSocieties 2: 11–20.

Cartwright

(2011) A philosopher’s view of the long road from RCTs to effectiveness. The Lancet 377: 1400–1401.

Cipriani

Furukawa

Salanti

(2018) Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. The Lancet 391: 1357–1366.

Dahabreh

Bibbins-Domingo

(2024) Causal inference about the effects of interventions from observational studies in medical journals. JAMA 331: 1845.

10.

Finberg

Gillman

(2011) Pharmacology of MAO-B inhibitors and the cheese reaction. International Review of Neurobiology 100: 169–190.

11.

Flockhart

(2012) Dietary restrictions and drug interactions with monoamine oxidase inhibitors: An update. Journal of Clinical Psychiatry 73(Suppl. 1): 17–24.

12.

Gill

Sabin

Schmid

(2005) Why clinicians are natural Bayesians. BMJ 330: 1080–1083.

13.

Gillman

(2011) CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity. Journal of Psychopharmacology 25: 429–433.

14.

Gillman

(2018) A reassesment of the safety profile of monoamine oxidase inhibitors: Elucidating tired old tyramine myths. Journal of Neural Transmission (Vienna) 125: 1707–1717.

15.

Gillman

Van den Eynde

(2023) A five-pronged critique of ‘Serotonin syndome—A focused review’. Basic & Clinical Pharmacology & Toxicology 133: 548–549.

16.

Goligher

Heath

Harhay

(2024) Bayesian statistics for clinical research. The Lancet 404: 1067–1076.

17.

Greenland

Senn

Rothman

, et al. (2016) Statistical tests, P values, confidence intervals, and power: A guide to misinterpretations. European Journal of Epidemiology 31: 337–350.

18.

Hill

(1965) The environment and disease: Association or causation? Proceedings of the Royal Society of Medicine 58: 295–300.

19.

Hill

(1966) Reflections on controlled trial. Annals of the Rheumatic Diseases 25: 107–113.

20.

Ioannidis

(2016) The mass production of redundant, misleading, and conflicted systematic reviews and meta-analyses. The Milbank Quarterly 94: 485–514.

21.

Lopez-Munoz

Alamo

Juckel

, et al. (2007) Half a century of antidepressant drugs: O n the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part I: monoamine oxidase inhibitors. Journal of Clinical Psychopharmacol 27: 555–559.

22.

Pearl

Glymour

Jewell

(2016) Causal Inference in Statistics: A Primer. John Wiley & Sons.

23.

Pearl

Mackenzie

(2018) The Book of Why: The New Science of Cause and Effect. Basic Books.

24.

Rawlins

(2008) De testimonio: On the evidence for decisions about the use of therapeutic interventions. The Lancet 372: 2152–2161.

25.

Robie

(1958) Iproniazid chemotherapy in melancholia. American Journal of Psychiatry 115: 402–409.

26.

Shulman

Fischer

Herrmann

, et al. (2009) Current prescription patterns and safety profile of irreversible monoamine oxidase inhibitors: A population-based cohort study of older adults. Journal of Clinical Psychiatry 70: 1681–1686.

27.

Van den Eynde

Abdelmoemin

Abraham

, et al. (2022a) The prescriber’s guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression. CNS Spectrums 28: 427–440.

28.

Van den Eynde

Gillman

Blackwell

(2022b) The prescriber’s guide to the MAOI diet-thinking through tyramine troubles. Psychopharmacology Bulletin 52: 73–116.